万邦德医药控股集团股份有限公司关于子公司获得发明专利的公告

Core Viewpoint - The company has received a patent for a cyclic peptide compound with specific disulfide bond structures, which has potential applications in various diseases and enhances drug targeting and stability [1]. Group 1: Patent Details - The patent involves a cyclic peptide compound with a specific disulfide bond structure and an efficient, controllable preparation method [1]. - The compound can precisely regulate various physiological functions through its high selectivity as a ligand for melanocortin receptors, offering new drug candidates for diseases such as neurodegenerative disorders, inflammation, autoimmune diseases, metabolic diseases, cancer, respiratory diseases, cardiovascular diseases, and reproductive system diseases [1]. - The unique structure of the compound enhances drug targeting, stability, and bioactivity, positively impacting the development of innovative drugs for conditions like Alzheimer's disease, amyotrophic lateral sclerosis, obesity, and pemphigus [1]. Group 2: Impact on the Company - The patent is not expected to have a significant immediate impact on the company's production and operations but will help protect intellectual property in new drug development [1]. - The patent will promote the company's self-research capabilities and technological innovation strength, accelerating new drug development and enhancing the company's core competitiveness [1].